J1434
J1434 – Inj, focinvez, 1mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 1 NDC crosswalked per 1 MG $2.456/unit ASP+6%
📋 J1434 summary
J1434 is a HCPCS Level II J-code used to bill focinvez, 1mg, billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J1434: Focinvez
Code J1434
Billing unit 1 MG Payment limit $2.456/unit NDC-Crosswalk 1
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ1434
DescriptorInj, focinvez, 1mg
Billing unit1 MG
Payment limit / unit$2.456
Est. ASP / unit$2.317 est.
Mapped NDCs1
Data periodQ3 2026
Last updated2026-08-20
💊 About Fosaprepitant Dimeglumine DRUG GUIDE
Fosaprepitant dimeglumine injection — available as the brands Emend, Focinvez, and Fosaprepitant Dimeglumine — is used to prevent nausea and vomiting caused by chemotherapy.
It is always given together with other anti-nausea medicines, not on its own.It is approved for both the immediate (acute) and delayed nausea and vomiting linked to highly emetogenic chemotherapy (HEC) — regimens most likely to cause severe nausea, including high-dose cisplatin — and for the delayed nausea and vomiting linked to moderately emetogenic chemotherapy (MEC).
It is not used to treat nausea or vomiting that has already started.
Clinical overview from our editorial drug guide for Fosaprepitant Dimeglumine. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$2.456
Est. ASP / unit
$2.317 est.
Est. after 2% sequester
$2.407
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J1434 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J1434 WITH EST. MEDICARE PAY
1 NDC map to J1434. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($2.456/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 70121-2631-01 | FOCINVEZ FOSAPREPITANT DIMEGLUMINE 150 mg/50mL INJECTION | Amneal | 1 VIAL, SINGLE-DOSE in 1 CARTON (70121-263... | 150 mg/50mL | 150 | $368.40 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$3.77M
Claims
9,640
Beneficiaries
3,548
Spend / beneficiary
$1,062.91
Spend / claim
$391.20
Trend by period
Where J1434 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #265 of 824
#260
ILUVIEN J7313
$4.02M
#261
AXTLE J9292
$4.01M
#262
TRELSTAR J3315
$3.85M
#263
RIABNI Q5123
$3.85M
#264
FORMOTEROL FUMARATE* J7606
$3.83M
#265
FOCINVEZ J1434
$3.77M
#266
APRETUDE J0739
$3.76M
#267
ELOCTATE J7205
$3.72M
#268
IODIXANOL(Q9967)* Q9967
$3.58M
#269
BACLOFEN(J0475)* J0475
$3.51M
#270
ALBUKED-25(P9047)* P9047
$3.5M
Total claims — #167 of 824
#162
CAMPTOSAR* J9206
10,330
#163
ZARXIO Q5101
10,231
#164
CUBICIN RF* J0878
9,691
#165
TRIESENCE J3300
9,687
#166
CYCLOSPORINE MODIFIE... J7515
9,668
#167
FOCINVEZ J1434
9,640
#168
ARALAST NP* J0256
9,390
#169
RENFLEXIS Q5104
9,046
#170
CYCLOPHOSPHAMIDE(J90... J9075
8,806
#171
AMINOPHYLLINE J0280
8,705
#172
LEVALBUTEROL HCL J7614
8,694
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $3.77M | 3,548 | 9,640 | $1,062.91 | $391.20 |
| 2025 (Q1-Q4) | $13.54M | 6,684 | 31,268 | $2,026.06 | $433.10 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$12.55M
Medicare paid
$9.82M
Submitted services
4,444,254
Denial rate
3.6%
Allowed / service
$2.93
Submitted charges
$43.93M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J1434 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 723,351 services across 6 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J1434 billing FAQ
What is HCPCS code J1434?
J1434 is a HCPCS Level II J-code used to bill Inj, focinvez, 1mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J1434?
One unit of J1434 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J1434 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J1434?
The Medicare Part B payment limit is $2.456 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $2.407 per unit. Payment limits are revised quarterly.
Which NDCs bill under J1434?
1 NDC currently map to J1434 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J1434 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.